Accéder au contenu
Merck

Principaux documents

Voir toute la documentation

890898C

Avanti

DOTMA

Avanti Research™ - A Croda Brand

Synonyme(s) :

1,2-di-O-octadecenyl-3-trimethylammonium propane (chloride salt)

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C42H84ClNO2
Numéro CAS:
104872-42-6
Poids moléculaire :
670.57
NACRES:
NA.25
MDL number:
MFCD00145456
UNSPSC Code:
12352211
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

assay

>99% (TLC)

form

liquid

packaging

pkg of 1 × 2.5 mL (890898C-25mg), pkg of 2 × 4 mL (890898C-200mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand

concentration

10 mg/mL (890898C-25mg), 25 mg/mL (890898C-200mg)

application(s)

advanced drug delivery

lipid type

transfection
cationic lipids

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H]C(C[N+](C)(C)C)(OCCCCCCCC/C=C\CCCCCCCC)COCCCCCCCC/C=C\CCCCCCCC.[Cl-]

InChI

1S/C42H84NO2.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-38-44-41-42(40-43(3,4)5)45-39-37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;/h20-23,42H,6-19,24-41H2,1-5H3;1H/q+1;/p-1/b22-20-,23-21-;

InChI key

LDGWQMRUWMSZIU-LQDDAWAPSA-M

Application

DOTMA is suitable for use in the synthesis of cationic microbubble.

Biochem/physiol Actions

DOTMA is a cationic lipid used as a non-viral vector for gene therapy. It exhibits effective in vitro and in vivo gene transfection. DOTMA induces a positive charge on the liposomes and thus promotes efficient liposome - cell membrane interaction.

Packaging

5 mL Clear Glass Sealed Ampule (890898C-200mg)
5 mL Clear Glass Sealed Ampule (890898C-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Still not finding the right product?

Explore all of our products under

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

target_organs

Liver,Kidney, Respiratory system

Classe de stockage

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

wgk

WGK 3

flash_point_f

does not flash

flash_point_c

does not flash

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Yun Wu et al.
Molecular therapy. Nucleic acids, 2, e84-e84 (2013-04-18)
MicroRNA-29b (miR-29b) expression has been shown to be reduced in non-small-cell lung cancer (NSCLC) tissues. Here, we have identified the oncogene cyclin-dependent protein kinase 6 (CDK6) as a direct target of miR-29b in lung cancer. We hypothesized that in vivo
The use of cationic microbubbles to improve ultrasound-targeted gene delivery to the ischemic myocardium
Sun L, et al.
Biomaterials, 34(8), 2107-2116 (2013)
Jayesh A Kulkarni et al.
ACS nano, 12(5), 4787-4795 (2018-04-04)
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration. However, the mechanism of formation and certain structural features of LNP-siRNA remain obscure.
Afficher tous les articles scientifiques apparentés